Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Exclusively Distribute Two DxS Cancer Companion Tests

NEW YORK (GenomeWeb News) – Roche said Monday that it will distribute two cancer mutation tests for the UK molecular diagnostics company DxS.
DxS makes companion diagnostics that can be used by oncologists to aid in the prognosis and development of treatments for cancer patients based on specific gene mutations, Roche said.
Roche will distribute the TheraScreen K-RAS Mutation Test, which detects seven mutations found in many cancer types and is used in colorectal cancer cases, through a worldwide, exclusive agreement.
The second test involved in the agreement, the TheraScreen EGFR 29 Mutation Test, detects mutations that correlate with responsiveness to EGFR tyrosine kinase inhibitors. This test may be used to help doctors choose lung cancer patients who are most likely to respond to treatment with EGFR tyrosine kinase inhibitors.
Roche has agreed to distribute this test exclusively to all global markets except the US, Canada, Mexico, and Hong Kong. Both of the companion tests have received European CE mark certification.
Financial terms of the agreement were not released.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.